IQVIA Holdings Inc. $IQV Stock Position Raised by TD Asset Management Inc

TD Asset Management Inc lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,277 shares of the medical research company’s stock after purchasing an additional 11,997 shares during the period. TD Asset Management Inc’s holdings in IQVIA were worth $22,276,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. Alliancebernstein L.P. raised its holdings in IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after buying an additional 19,573 shares during the period. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA in the second quarter worth approximately $515,772,000. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after acquiring an additional 581,157 shares during the period. Nordea Investment Management AB lifted its position in shares of IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after acquiring an additional 253,759 shares in the last quarter. Finally, Cantillon Capital Management LLC boosted its stake in IQVIA by 27.3% in the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after purchasing an additional 413,256 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research analyst reports. Truist Financial reduced their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. TD Cowen increased their price objective on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Citigroup decreased their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Mizuho set a $215.00 target price on IQVIA in a report on Monday, February 23rd. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $231.80.

IQVIA Stock Performance

IQV stock opened at $179.09 on Friday. The company has a market capitalization of $30.39 billion, a price-to-earnings ratio of 22.79, a P/E/G ratio of 1.72 and a beta of 1.37. The firm has a 50 day moving average of $212.19 and a two-hundred day moving average of $208.00. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.